» Articles » PMID: 33142714

Associations of HDL Subspecies Defined by ApoC3 with Non-Alcoholic Fatty Liver Disease: The Multi-Ethnic Study of Atherosclerosis

Overview
Journal J Clin Med
Specialty General Medicine
Date 2020 Nov 4
PMID 33142714
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, we reported that inverse associations of high-density lipoprotein (HDL) with cardiovascular disease and diabetes were only observed for HDL that lacked the pro-inflammatory protein apolipoprotein C3 (apoC3). To provide further insight into the cardiometabolic properties of HDL subspecies defined by the presence or absence of apoC3, we aimed to examine these subspecies with liver fat content and non-alcoholic fatty liver disease (NAFLD). We investigated cross-sectional associations between ELISA-measured plasma levels of apoA1 in HDL that contained or lacked apoC3 and computed tomography-determined liver fat content and NAFLD (<51 HU) at baseline (2000-2002) among 5007 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) without heavy alcohol consumption (>14 drinks/week in men and >7 drinks/week in women). In multivariable-adjusted regression models, apoA1 in HDL that contained or lacked apoC3 was differentially associated with liver fat content ( = 0.048). While apoA1 in HDL that lacked apoC3 was inversely associated with liver fat content ( < 0.0001), apoA1 in HDL that contained apoC3 was not statistically significantly associated with liver fat content ( = 0.57). Higher apoA1 in HDL that lacked apoC3 was related to a lower prevalence of NAFLD (OR per SD: 0.80; 95% CI: 0.72, 0.89), whereas no association was found for apoA1 in HDL that contained apoC3 (OR per SD: 0.95; 95% CI: 0.85, 1.05; = 0.09). Higher apoA1 in HDL that lacked apoC3 was associated with less liver fat content and a lower prevalence of NAFLD. This finding extends the inverse association of HDL lacking apoC3 from cardiovascular disease to NAFLD. Lack of biopsy-proven hepatic steatosis and fibrosis data requires the replication of our study in further studies.

Citing Articles

High-density lipoproteins and non-alcoholic fatty liver disease.

Hoekstra M, Van Eck M Atheroscler Plus. 2023; 53:33-41.

PMID: 37663008 PMC: 10469384. DOI: 10.1016/j.athplu.2023.08.001.


Apolipoprotein C3 is negatively associated with estrogen and mediates the protective effect of estrogen on hypertriglyceridemia in obese adults.

Li J, Sun H, Wang Y, Liu J, Wang G Lipids Health Dis. 2023; 22(1):29.

PMID: 36855114 PMC: 9972754. DOI: 10.1186/s12944-023-01797-0.


Associations between Alcohol Consumption and HDL Subspecies Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study.

Wilkens T, Sorensen H, Jensen M, Furtado J, Dragsted L, Mukamal K Curr Probl Cardiol. 2022; 48(1):101395.

PMID: 36096454 PMC: 9691554. DOI: 10.1016/j.cpcardiol.2022.101395.


Increased protein expression of ABCA1, HMG-CoA reductase, and CYP46A1 induced by garlic and allicin in the brain mouse and astrocytes-isolated from C57BL/6J.

Nazeri Z, Azizidoost S, Cheraghzadeh M, Mohammadi A, Kheirollah A Avicenna J Phytomed. 2021; 11(5):473-483.

PMID: 34745919 PMC: 8554280. DOI: 10.22038/AJP.2021.17834.


Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease.

Karami S, Poustchi H, Sarmadi N, Radmard A, Ali Yari F, Pakdel A Diabetol Metab Syndr. 2021; 13(1):121.

PMID: 34702329 PMC: 8549143. DOI: 10.1186/s13098-021-00741-5.


References
1.
Zeb I, Li D, Nasir K, Katz R, Larijani V, Budoff M . Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis. Acad Radiol. 2012; 19(7):811-8. PMC: 3377794. DOI: 10.1016/j.acra.2012.02.022. View

2.
Koch M, Furtado J, Jiang G, Gray B, Cai T, Sacks F . Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III. J Lipid Res. 2017; 58(6):1196-1203. PMC: 5454517. DOI: 10.1194/jlr.P073288. View

3.
Lamarche B, Uffelman K, Carpentier A, Cohn J, Steiner G, Barrett P . Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999; 103(8):1191-9. PMC: 408274. DOI: 10.1172/JCI5286. View

4.
Agrawal N, Freitas Corradi P, Gumaste N, Goldberg I . Triglyceride Treatment in the Age of Cholesterol Reduction. Prog Cardiovasc Dis. 2016; 59(2):107-118. PMC: 5364728. DOI: 10.1016/j.pcad.2016.08.003. View

5.
Bild D, Bluemke D, Burke G, Detrano R, Diez Roux A, Folsom A . Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156(9):871-81. DOI: 10.1093/aje/kwf113. View